Sangamo Therapeutics Inc (NASDAQ:SGMO) price on Thursday, February 27, fall -2.24% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.96.
A look at the stock’s price movement, the close in the last trading session was $0.98. Turning to its 52-week performance, $3.18 and $0.30 were the 52-week high and 52-week low respectively. Overall, SGMO moved -15.30% over the past month.
Sangamo Therapeutics Inc’s market cap currently stands at around $199.70 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 11.7M for the company’s revenue for the quarter, with a low and high estimate of 200k and 20M respectively. The average forecast suggests up to a 472.97% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 62.32M, representing a -64.64% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SGMO is a 50% Sell. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 1 recommend SGMO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SGMO’s current price about -15.50% and -33.24% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 33.09, while 7-day volatility ratio is 9.44% and 8.39% in the 30-day chart. Further, Sangamo Therapeutics Inc (SGMO) has a beta value of 1.51, and an average true range (ATR) of 0.11. Analysts have given the company’s stock an average 52-week price target of $2.5, forecast between a low of $2 and high of $3. Looking at the price targets, the low is -108.33% off current price level while to achieve the yearly target high, price needs to move -212.5%. Nonetheless, investors will most likely welcome a -160.42% jump to $2.5 which is the analysts’ median price.
If we refocus on Sangamo Therapeutics Inc (NASDAQ:SGMO), historical trading data shows that trading volumes averaged 6.50 million over the past 3 months. The company’s latest data on shares outstanding shows there are 208.62 million shares.
The 4.14% of Sangamo Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 29.74% of the company’s shares. Current price change has pushed the stock -6.17% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SGMO stock continues to rise going into the next quarter.
